Topigs Norsvin booked an operating profit of € 6.7 million in 2018. The gross margin increased to € 73.9 million, an increase of 4% compared to 2017. Topigs Norsvin performed better than was budgeted and the organization once again experienced a good year. CEO Martin Bijl stated that Topigs Norsvin is a healthy organization with a superb solvency and liquidity. This is a good foundation for further growth in the coming years.
Thanks to these results, Topigs Norsvin can continue to make considerable investments in product innovation and improvement. In 2018, it opened Delta Canada, which at a cost of € 10 million is the biggest investment in the history of Topigs Norsvin. Delta Canada is equipped with CT scan technology that makes it possible to collect very detailed data. This data can be used, for example, to further accelerate the genetic progress at clients.
The 2019 Research & Development budget has been increased with 7% to more than € 22.5 million to realize the further growth of Topigs Norsvin. Martin Bijl: “With the growth of the R&D budget, Topigs Norsvin wants to focus even more effectively on innovation and product improvement. Our clients will gain maximum benefit from this due to the introduction of new and improved products, concepts, and services.”